Genomic biomarkers refer to diagnostic indicators that are obtained from various gene properties, including gene expression, gene mutation, and gene regulation. Genomic biomarkers have the potential to facilitate the identification of neurological, oncological, and cardiovascular diseases. Genomic biomarkers play a crucial role in enabling timely disease diagnosis, monitoring disease progression, and evaluating the biological response to therapeutic interventions. Genomic biomarkers can be utilized either independently or in combination with other biomarkers, including protein biomarkers. Genomic biomarkers such as mRNA, miRNA, cell-free DNA, and long-coding RNA have been employed for clinical diagnosis. The market expansion of genomic biomarkers is expected to be driven by chronic diseases in the forthcoming years. The expansion of the industry is expected to occur due to heightened research and development efforts aimed at identifying novel genetic biomarkers and improving the specificity of genomic biomarkers. The progress in healthcare and genomics is expected to result in an increase in genomic biomarkers.
The global Genomic biomarker Market is anticipated to grow at a CAGR of 9.5% during the period of forecast (2021-2028).
Major Players in the Genomic Biomarker Industry:
1.Thermo Fisher Scientific
Thermo Fisher Scientific is an American supplier of scientific instrumentation, reagents and consumables, and software services, was founded in 1956 and headquartered in Massachusetts, United States. It operates in 59 countries worldwide, notably in the U.S. and in Europe, and China. In June 2023, Thermo Fisher Scientific launched revolutionary mass spectrometer for biological discovery. The Thermo ScientificTM OrbitrapTM AstralTM mass spectrometer, a 15-year mass spectrometry breakthrough, was introduced by Thermo Fisher Scientific. The Astral analyzer's quick throughput, high sensitivity, and deep proteome coverage enable researchers worldwide to find previously undetected proteins and make breakthrough discoveries faster than ever. This data can help researchers find new clinical biomarkers, detect diseases earlier, and discover novel treatments for cardiovascular disease and cancer.
2. F. Hoffmann-La Roche AG
F. Hoffmann-La Roche AG commonly known as Roche, is a Swiss multinational healthcare company, founded in 1896 and is headquartered in Basel, Switzerland. It operates in more than 150 countries. In August 2022, the FDA approved Roche's companion diagnostic to identify dMMR solid tumor patients eligible for anti-PD-1 immunotherapy.
3. AROS Applied Biotechnology A/S
AROS Applied Biotechnology A/S is one of the providers of genomic services for the pharma industry and universities, was founded in 2000 and headquartered in Denmark. It operates in 36 countries.
4. Myriad Genetics, Inc.
Myriad Genetics, Inc. is an American genetic testing and precision medicine company, was founded in 1991 and headquartered in Salt Lake City, Utah, United States. It operates in 128 countries. Myriad Genetics extended coverage for the BRACAnalysis® Diagnostic System in Early-Stage Breast Cancer as a Companion Diagnostic to Lynparza® in Japan in August 2022. Also, at ASCO 2023, in June 2023, Myriad Genetics presented its most recent oncology portfolio developments and new data.
5. QIAGEN
QIAGEN is a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research, was founded in 1984 and headquartered in Maryland, United States. It operates in over 25 countries. In April 2023, QIAGEN convened the Global Solid Tumor Summit and addressed the most pressing issues in cancer diagnostics and treatment.
6. Eurofins Scientific
Eurofins Scientific is a French group of laboratories providing testing and
Support services to the pharmaceutical, food, environmental, agriscience and consumer products industries band to governments. It was founded in 1987 and headquartered in Luxembourg. It operates in more than 65 countries.
7. Genomic Health
Genomic Health was a company focusing on genetic research specifically in cancer detection, was founded in 2000 and headquartered in California, United States. It operated in more than 80 countries. The company was acquired by and merged with Exact Sciences Corporation in 2019.
8. Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets, was founded in 1952 and headquartered in California, United States. It has operations worldwide. In August 2022, Bio-Rad acquires Curiosity Diagnostics for the medical diagnostic and healthcare industries for a maximum total consideration of $170 million, consisting of approximately $100 million in cash and up to $70 million in potential future milestone payments.
9. Epigenomics AG
Epigenomics AG is a molecular diagnostics company,founded in 1998 and headquarter in ; Seattle, Washington. It operates in. many European countries. In September 2022, Epigenomics launched a prospective, multi-center clinical trial of its "Next-Generation" blood-based colorectal cancer test.
*Definition: A genomic biomarker is a measurable property of DNA or RNA that shows normal biological processes, pathological processes, or the body's reaction to a treatment or other intervention.
